A European, multicentre, retrospective, non‐interventional study ( EU‐TREAT ) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aims: To evaluate the clinical effectiveness of switching to insulin degludec (IDeg) in insulin‐treated patients with either type 1 diabetes (T1DM) or type 2 diabetes (T2DM) under conditions of routine clinical care. Materials and Methods: This was a multicentre, retrospective, chart review study. In all patients, basal insulin was switched to IDeg at least 6 months before the start of data collection. Baseline was defined as the most recent recording during the 3‐month period before first prescription of IDeg. Values are presented as mean [95%CI]. Results: T1DM (n = 1717): HbA1c decreased by −2.2 [−2.6; −2.0] mmol/mol (−0.20 [−0.24; −0.17]%) at 6 months vs baseline ( P < .001). Rate ratio of overall (0.79 [0.69; 0.89]), non‐severe nocturnal (0.54 [0.42; 0.69]) and severe (0.15 [0.09; 0.24]) hypoglycaemia was significantly lower in the 6‐month post‐switch period vs the pre‐switch period ( P < .001 for all). Total daily insulin dose decreased by −4.88 [−5.52; −4.24] U (−11%) at 6 months vs baseline ( P < .001). T2DM (n = 833): HbA1c decreased by −5.6 [−6.3; −4.7] mmol/mol (−0.51 [−0.58; −0.43] %) at 6 months vs baseline ( P < .001). Rate ratio of overall (0.39 [0.27; 0.58], P < .001), non‐severe nocturnal (0.10 [0.06; 0.16], P < .001) and severe (0.075 [0.01; 0.43], P = .004) hypoglycaemia was significantly lower in the 6‐month post‐switch period vs the pre‐switch period. Total daily insulin dose decreased by −2.48 [−4.24; −0.71] U (−3%) at 6 months vs baseline ( P = .006). Clinical outcomes for T1DM and T2DM at 12 months were consistent with results at 6 months. Conclusions: This study demonstrates that switching patients to IDeg from other basal insulins improves glycaemic control and significantly reduces the risk of hypoglycaemia in routine clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544 · cited 1×
“Therefore, it can be challenging to extrapolate the results to an unselected population.(9) Real-world studies are a valuable additional source of evidence that complement clinical trial data by assessing the external validity of new therapies, thus bridging the knowledge gap between RCTs and clinical practice.”
BackgroundHex, N., Bartlett, C., Wright, D., Taylor, M., & Varley, D. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03698.x · Cited by 819
Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794 · cited 1×
“3) kg/m2, with HbA1c 68 (15) mmol/mol (8.”
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655
Efficacy and safety of degludec versus glargine in type 2 diabetes.
Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615692 · Cited by 574
Correlates of Insulin Injection Omission
Peyrot, M., Rubin, R. R., Kruger, D. F., & Travis, L. B. (2010) · Diabetes Care · doi:10.2337/dc09-1348 · Cited by 407
Heise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397
Ratner, R. E., Gough, S. C. L., Mathieu, C., Del Prato, S., Bode, B., Mersebach, H., Endahl, L., & Zinman, B. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12032 · Cited by 346
Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Ways, K., Desai, M., Shaw, W., Capuano, G., Alba, M., et al. (2015) · Diabetes Care · doi:10.2337/dc14-1237 · Cited by 233
Cited by
Fadini, G. P., Feher, M., Hansen, T. K., de Valk, H. W., Koefoed, M. M., Wolden, M., Zimmermann, E., & Jendle, J. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01021 · Cited by 27
Self-citationthe RESTORE-1 Study Group, Laviola, L., Porcellati, F., Bruttomesso, D., Larosa, M., Rossi, M. C., & Nicolucci, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00982-z · Cited by 16
“[27]; severe hypoglycemic events during 6 months.”
Thalange, N., Gundgaard, J., Parekh, W., & Tutkunkardas, D. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000664 · Cited by 7
Metadata
- Authors
- Siegmund, T., Tentolouris, N., Knudsen, S. T., Lapolla, A., Prager, R., Phan, T., Wolden, M. L., Schultes, B., & for the EU‐TREAT study group
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-11-21
- Volume
- 20
- Issue
- 3
- Pages
- 689-697
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2767832909
- Cited by
- 44
- References
- 11
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.